Kodiak Sciences Inc.
KOD
Classifica tra le azioni
#3260
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical... Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
Prezzo delle azioni
$85.93
Ultima sincronizzazione: 2026-10-16
Capitalizzazione di mercato
$5.40B
Variazione (1 giorno)
-2.49%
Variazione (1 anno)
509.40%
Paese
US
Scambia Kodiak Sciences Inc. (KOD)
Categoria
Healthcare
EPS per Kodiak Sciences Inc. (KOD)
EPS al June 2026 TTM: $-4.19
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Kodiak Sciences Inc., l’EPS attuale della società (TTM) è $-4.19. Alla fine del 2023, la società aveva un EPS di $-4.97 una diminuzione rispetto a rispetto a quello del 2022, che era di $-6.39.
Storico EPS per Kodiak Sciences Inc. da 2016 a 2026
EPS alla fine di ogni anno
| Anno | EPS | Cambia |
|---|---|---|
| 2026 (TTM) | $-4.19 | 25.07% |
| 2024 | $-3.35 | -32.60% |
| 2023 | $-4.97 | -22.22% |
| 2022 | $-6.39 | 23.84% |
| 2021 | $-5.16 | 77.32% |
| 2020 | $-2.91 | 136.59% |
| 2019 | $-1.23 | 6.03% |
| 2018 | $-1.16 | 10.48% |
| 2017 | $-1.05 | -54.35% |
| 2016 | $-2.30 | 0.00% |
EPS per aziende simili o concorrenti
| Azienda | EPS | Differenza di EPS | Il paese |
|---|---|---|---|
| $17.32 | -513.37% |
US
|
|
| $-7.98 | 90.45% |
US
|
|
| $-5.29 | 26.25% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -762.05% |
NL
|
